264 related articles for article (PubMed ID: 23149009)
1. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.
Abdel-Rahman SM; Amidon GL; Kaul A; Lukacova V; Vinks AA; Knipp GT;
Clin Ther; 2012 Nov; 34(11):S11-24. PubMed ID: 23149009
[TBL] [Abstract][Full Text] [Related]
2. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
3. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
4. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
Liu XI; van den Anker JN; Burckart GJ; Dallmann A
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
[TBL] [Abstract][Full Text] [Related]
6. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
7. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
Giacoia GP; Taylor-Zapata P; Mattison D
Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
[TBL] [Abstract][Full Text] [Related]
8. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
9. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility.
Maharaj AR; Edginton AN; Fotaki N
Pharm Res; 2016 Jan; 33(1):52-71. PubMed ID: 26220249
[TBL] [Abstract][Full Text] [Related]
11. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
12. Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts.
Batchelor H; Ernest T; Flanagan T; Klein S; Turner R; Fotaki N; Storey D;
Int J Pharm; 2016 Sep; 511(2):1151-7. PubMed ID: 27349792
[TBL] [Abstract][Full Text] [Related]
13. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
14. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
[TBL] [Abstract][Full Text] [Related]
15. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.
Gandhi SV; Rodriguez W; Khan M; Polli JE
AAPS PharmSciTech; 2014 Jun; 15(3):601-11. PubMed ID: 24557773
[TBL] [Abstract][Full Text] [Related]
16. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
17. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
18. Development and applications of a physiologically-based model of paediatric oral drug absorption.
Johnson TN; Bonner JJ; Tucker GT; Turner DB; Jamei M
Eur J Pharm Sci; 2018 Mar; 115():57-67. PubMed ID: 29309876
[TBL] [Abstract][Full Text] [Related]
19. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system.
Del Moral Sanchez JM; Gonzalez-Alvarez I; Cerda-Revert A; Gonzalez-Alvarez M; Navarro-Ruiz A; Amidon GL; Bermejo M
Br J Clin Pharmacol; 2018 Oct; 84(10):2231-2241. PubMed ID: 29846973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
